Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.

Afinitor

Last reviewed on RxList: 2/3/2020
Afinitor Side Effects Center

What Is Afinitor?

Afinitor (everolimus) is an antineoplastic agent (cancer medication) used to treat advanced kidney cancer, and is usually given after sorafenib (Nexavar) or sunitinib (Sutent) have been tried without successful treatment of symptoms.

What Are Side Effects of Afinitor?

Common side effects of Afinitor include:

  • diarrhea,
  • constipation,
  • nausea,
  • vomiting,
  • decreased appetite,
  • weight loss,
  • changes in taste or unusual taste in your mouth,
  • nosebleeds,
  • dry skin,
  • acne,
  • itching or skin rash,
  • headache,
  • pain or sores in the mouth and throat,
  • cold symptoms (stuffy nose, sneezing, sore throat),
  • temporary hair loss, or
  • pain in your arms and legs.

Tell your doctor if you have serious side effects of Afinitor including:

  • swelling hands/ankles/feet,
  • missed/heavy/painful periods,
  • easy bruising or bleeding,
  • unusual tiredness,
  • mental/mood changes, or
  • wound problems (such as slowed wound healing).

Dosage for Afinitor

The recommended dose of Afinitor is 10 mg, taken once daily.

What Drugs, Substances, or Supplements Interact with Afinitor?

Afinitor may interact with aminoglutethimide, aprepitant, bosentan, conivaptan, dexamethasone, diclofenac, enoxacin, imatinib, isoniazid, phenylbutazone, St. John's wort, antidepressants, antibiotics, barbiturates, heart or blood pressure medications, HIV or AIDS medications, medicines to treat narcolepsy, or seizure medications. Tell your doctor all medications you use.

Afinitor During Pregnancy and Breastfeeding

Afinitor is not recommended for use during pregnancy. It may harm a fetus. Use at least 2 forms of birth control (such as condoms, birth control pills) while taking this medication and for 8 weeks after stopping treatment. If you become pregnant or think you may be pregnant, tell your doctor. It is unknown if this medication passes into breast milk. Because of the possible risk to the infant, breastfeeding while using this drug is not recommended.

Additional Information

Our Afinitor (everolimus) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

Skin Cancer Symptoms, Types, Images See Slideshow
Afinitor Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; chest pain, difficult breathing; swelling of your face, lips, tongue, or throat. You may be more likely to have some of these symptoms if you also take an "ACE inhibitor" heart or blood pressure medication.

Stop using Afinitor and call your doctor at once if you have:

  • blisters or ulcers in your mouth, red or swollen gums, trouble swallowing;
  • lung problems--new or worsening cough, chest pain, wheezing, feeling short of breath;
  • signs of infection--fever, chills, tiredness, joint pain, skin rash;
  • kidney problems--little or no urination; swelling in your feet or ankles;
  • liver problems--nausea, loss of appetite, stomach pain (upper right side), dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
  • low blood cell counts--flu-like symptoms, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, feeling light-headed;
  • any wound that will not heal; or
  • a surgical incision that is red, warm, swollen, painful, bleeding, or oozing pus.

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common side effects may include:

  • fever, cough, infections, feeling weak or tired;
  • mouth sores;
  • nausea, loss of appetite;
  • swelling anywhere in your body;
  • rash;
  • missed menstrual periods;
  • headache; or
  • high blood sugar--increased thirst, increased urination, dry mouth, fruity breath odor.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Afinitor (Everolimus Tablets)

Afinitor Professional Information

SIDE EFFECTS

The following serious adverse reactions are described elsewhere in the labeling:

  • Non-Infectious Pneumonitis [see WARNINGS AND PRECAUTIONS].
  • Infections [see WARNINGS AND PRECAUTIONS].
  • Severe Hypersensitivity Reactions [see WARNINGS AND PRECAUTIONS].
  • Angioedema with Concomitant Use of ACE inhibitors [see WARNINGS AND PRECAUTIONS].
  • Stomatitis [see WARNINGS AND PRECAUTIONS].
  • Renal Failure [see WARNINGS AND PRECAUTIONS].
  • Impaired Wound Healing [see WARNINGS AND PRECAUTIONS].
  • Metabolic Disorders [see WARNINGS AND PRECAUTIONS].
  • Myelosuppression [see WARNINGS AND PRECAUTIONS].

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other trials and may not reflect the rates observed in clinical practice.

Hormone Receptor-Positive, HER2-Negative Breast Cancer

The safety of AFINITOR (10 mg orally once daily) in combination with exemestane (25 mg orally once daily) (n = 485) vs. placebo in combination with exemestane (n = 239) was evaluated in a randomized, controlled trial (BOLERO-2) in patients with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer. The median age of patients was 61 years (28 to 93 years), and 75% were White. The median follow-up was approximately 13 months.

The most common adverse reactions (incidence ≥ 30%) were stomatitis, infections, rash, fatigue, diarrhea, and decreased appetite. The most common Grade 3-4 adverse reactions (incidence ≥ 2%) were stomatitis, infections, hyperglycemia, fatigue, dyspnea, pneumonitis, and diarrhea. The most common laboratory abnormalities (incidence ≥ 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia. The most common Grade 3-4 laboratory abnormalities (incidence ≥ 3%) were lymphopenia, hyperglycemia, anemia, hypokalemia, increased AST, increased ALT, and thrombocytopenia.

Fatal adverse reactions occurred in 2% of patients who received AFINITOR. The rate of adverse reactions resulting in permanent discontinuation was 24% for the AFINITOR arm. Dose adjustments (interruptions or reductions) occurred in 63% of patients in the AFINITOR arm.

Adverse reactions reported with an incidence of ≥ 10% for patients receiving AFINITOR versus placebo are presented in Table 6. Laboratory abnormalities are presented in Table 7. The median duration of treatment with AFINITOR was 23.9 weeks; 33% were exposed to AFINITOR for a period of ≥ 32 weeks.

Table 6: Adverse Reactions Reported in ≥ 10% of Patients with Hormone Receptor-Positive Breast Cancer in BOLERO-2

  AFINITOR with Exemestane
N = 482
Placebo with Exemestane
N = 238
All Grades
%
Grade 3-4
%
All Grades
%
Grade 3-4
%
Gastrointestinal
  Stomatitisa 67 8d 11 0.8
  Diarrhea 33 2 18 0.8
  Nausea 29 0.4 28 1
  Vomiting 17 1 12 0.8
  Constipation 14 0.4d 13 0.4
  Dry mouth 11 0 7 0
General
  Fatigue 36 4 27 1d
  Edema peripheral 19 1d 6 0.4d
  Pyrexia 15 0.2d 7 0.4d
  Asthenia 13 2 4 0
Infections
  Infectionsb 50 6 25 2d
Investigations
  Weight loss 25 1d 6 0
Metabolism and nutrition
  Decreased appetite 30 1d 12 0.4d
  Hyperglycemia 14 5 2 0.4d
Musculoskeletal and connective tissue
  Arthralgia 20 0.8d 17 0
  Back pain 14 0.2d 10 0.8d
  Pain in extremity 9 0.4d 11 2d
Nervous system
  Dysgeusia 22 0.2d 6 0
  Headache 21 0.4d 14 0
Psychiatric
  Insomnia 13 0.2d 8 0
Respiratory, thoracic and mediastinal
  Cough 24 0.6d 12 0
  Dyspnea 21 4 11 1
  Epistaxis 17 0 1 0
  Pneumonitisc 19 4 0.4 0
Skin and subcutaneous tissue
  Rash 39 1d 6 0
  Pruritus 13 0.2d 5 0
  Alopecia 10 0 5 0
Vascular
  Hot flush 6 0 14 0
Grading according to NCI CTCAE Version 3.0
a Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis, and lip ulceration
b Includes all reported infections including, but not limited to, urinary tract infections, respiratory tract (upper and lower) infections, skin infections, and gastrointestinal tract infections.
c Includes pneumonitis, interstitial lung disease, lung infiltration, and pulmonary fibrosis
d No Grade 4 adverse reactions were reported.

Table 7: Selected Laboratory Abnormalities Reported in ≥ 10% of Patients with Hormone Receptor-Positive Breast Cancer in BOLERO-2

  AFINITOR with Exemestane
N = 482
Placebo with Exemestane
N = 238
All Grades
%
Grade 3-4
%
All Grades
%
Grade 3-4
%
Hematologya
  Anemia 68 6 40 1
  Leukopenia 58 2b 28 6
  Thrombocytopenia 54 3 5 0.4
  Lymphopenia 54 12 37 6
  Neutropenia 31 2b 11 2
Chemistry
  Hypercholesterolemia 70 1 38 2
  Hyperglycemia 69 9 44 1
  Increased aspartate transaminase (AST) 69 4 45 3
  Increased alanine transaminase (ALT) 51 4 29 5b
  Hypertriglyceridemia 50 0.8b 26 0
  Hypoalbuminemia 33 0.8b 16 0.8b
  Hypokalemia 29 4 7 1b
  Increased creatinine 24 2 13 0
Grading according to NCI CTCAE Version 3.0.
a Reflects corresponding adverse drug reaction reports of anemia, leukopenia, lymphopenia, neutropenia, and thrombocytopenia (collectively as pancytopenia), which occurred at lower frequency.
b No Grade 4 laboratory abnormalities were reported.

Topical Prophylaxis For Stomatitis

In a single arm study (SWISH; N = 92) in postmenopausal women with hormone receptor-positive, HER2-negative breast cancer beginning AFINITOR (10 mg orally once daily) in combination with exemestane (25 mg orally once daily), patients started dexamethasone 0.5 mg/5mL alcohol-free mouthwash (10 mL swished for 2 minutes and spat, 4 times daily for 8 weeks) concurrently with AFINITOR and exemestane. No food or drink was to be consumed for at least 1 hour after swishing and spitting the dexamethasone mouthwash. The primary objective of this study was to assess the incidence of Grade 2 to 4 stomatitis within 8 weeks. The incidence of Grade 2 to 4 stomatitis within 8 weeks was 2%, which was lower than the 33% reported in the BOLERO-2 trial. The incidence of Grade 1 stomatitis was 19%. No cases of Grade 3 or 4 stomatitis were reported. Oral candidiasis was reported in 2% of patients in this study compared to 0.2% in the BOLERO2 trial.

Coadministration of AFINITOR/AFINITOR DISPERZ and dexamethasone alcohol-free oral solution has not been studied in pediatric patients.

Pancreatic Neuroendocrine Tumors (PNET)

In a randomized, controlled trial (RADIANT-3) of AFINITOR (n = 204) vs. placebo (n = 203) in patients with advanced PNET the median age of patients was 58 years (20 to 87 years), 79% were White, and 55% were male. Patients on the placebo arm could cross over to open-label AFINITOR upon disease progression.

The most common adverse reactions (incidence ≥ 30%) were stomatitis, rash, diarrhea, fatigue, edema, abdominal pain, nausea, fever, and headache. The most common Grade 3-4 adverse reactions (incidence ≥ 5%) were stomatitis and diarrhea. The most common laboratory abnormalities (incidence ≥ 50%) were anemia, hyperglycemia, increased alkaline phosphatase, hypercholesterolemia, decreased bicarbonate, and increased AST. The most common Grade 3-4 laboratory abnormalities (incidence ≥ 3%) were hyperglycemia, lymphopenia, anemia, hypophosphatemia, increased alkaline phosphatase, neutropenia, increased AST, hypokalemia, and thrombocytopenia.

Deaths during double-blind treatment where an adverse reaction was the primary cause occurred in seven patients on AFINITOR. Causes of death on the AFINITOR arm included one case of each of the following: acute renal failure, acute respiratory distress, cardiac arrest, death (cause unknown), hepatic failure, pneumonia, and sepsis. After cross-over to open-label AFINITOR, there were three additional deaths, one due to hypoglycemia and cardiac arrest in a patient with insulinoma, one due to myocardial infarction with congestive heart failure, and the other due to sudden death. The rate of adverse reactions resulting in permanent discontinuation was 20% for the AFINITOR group. Dose delay or reduction was necessary in 61% of AFINITOR patients. Grade 3-4 renal failure occurred in six patients in the AFINITOR arm. Thrombotic events included five patients with pulmonary embolus in the AFINITOR arm as well as three patients with thrombosis in the AFINITOR arm.

Table 8 compares the incidence of adverse reactions reported with an incidence of ≥ 10% for patients receiving AFINITOR vs. placebo. Laboratory abnormalities are summarized in Table 9. The median duration of treatment in patients who received AFINITOR was 37 weeks.

In female patients aged 18 to 55 years, irregular menstruation occurred in 5 of 46 (11%) AFINITOR-treated females.

Table 8: Adverse Reactions Reported in ≥ 10% of Patients with PNET in RADIANT-3

  AFINITOR
N = 204
Placebo
N = 203
All Grades
%
Grade 3-4
%
All Grades
%
Grade 3-4
%
Gastrointestinal
  Stomatitisa 70 7d 20 0
  Diarrheab 50 6 25 3d
  Abdominal pain 36 4d 32 7
  Nausea 32 2d 33 2d
  Vomiting 29 1d 21 2d
  Constipation 14 0 13 0.5d
  Dry mouth 11 0 4 0
General
  Fatigue/malaise 45 4 27 3
  Edema (general and peripheral) 39 2 12 1d
  Fever 31 1 13 0.5d
  Asthenia 19 3d 20 3d
Infections
  Nasopharyngitis/rhinitis/URI 25 0 13 0
  Urinary tract infection 16 0 6 0.5d
Investigations
  Weight loss 28 0.5d 11 0
Metabolism and nutrition
  Decreased appetite 30 1d 18 1d
  Diabetes mellitus 10 2d 0.5 0
Musculoskeletal and connective tissue
  Arthralgia 15 1 7 0.5d
  Back pain 15 1d 11 1d
  Pain in extremity 14 0.5d 6 1d
  Muscle spasms 10 0 4 0
Nervous system
  Headache/migraine 30 0.5d 15 1d
  Dysgeusia 19 0 5 0
  Dizziness 12 0.5d 7 0
Psychiatric
  Insomnia 14 0 8 0
Respiratory, thoracic and mediastinal
  Cough/productive cough 25 0.5d 13 0
  Epistaxis 22 0 1 0
  Dyspnea/dyspnea exertional 20 3 7 0.5d
  Pneumonitisc 17 4 0 0
  Oropharyngeal pain 11 0 6 0
Skin and subcutaneous
  Rash 59 0.5 19 0
  Nail disorders 22 0.5 2 0
  Pruritus/pruritus generalized 21 0 13 0
  Dry skin/xeroderma 13 0 6 0
Vascular
  Hypertension 13 1 6 1d
Grading according to NCI CTCAE Version 3.0
a Includes stomatitis, aphthous stomatitis, gingival pain/swelling/ulceration, glossitis, glossodynia, lip ulceration, mouth ulceration, tongue ulceration, and mucosal inflammation.
b Includes diarrhea, enteritis, enterocolitis, colitis, defecation urgency, and steatorrhea.
c Includes pneumonitis, interstitial lung disease, pulmonary fibrosis, and restrictive pulmonary disease.
d No Grade 4 adverse reactions were reported.

Table 9: Selected Laboratory Abnormalities Reported in ≥ 10% of Patients with PNET in RADIANT-3

  AFINITOR
N = 204
Placebo
N = 203
All Grades
%
Grade 3-4
%
All Grades
%
Grade 3-4
%
Hematology
  Anemia 86 15 63 1
  Lymphopenia 45 16 22 4
  Thrombocytopenia 45 3 11 0
  Leukopenia 43 2 13 0
  Neutropenia 30 4 17 2
Chemistry
  Hyperglycemia (fasting) 75 17 53 6
  Increased alkaline phosphatase 74 8 66 8
  Hypercholesterolemia 66 0.5 22 0
  Bicarbonate decreased 56 0 40 0
  Increased AST 56 4 41 4
  Increased ALT 48 2 35 2
  Hypophosphatemia 40 10 14 3
  Hypertriglyceridemia 39 0 10 0
  Hypocalcemia 37 0.5 12 0
  Hypokalemia 23 4 5 0
  Increased creatinine 19 2 14 0
  Hyponatremia 16 1 16 1
  Hypoalbuminemia 13 1 8 0
  Hyperbilirubinemia 10 1 14 2
  Hyperkalemia 7 0 10 0.5
Grading according to NCI CTCAE Version 3.0

Neuroendocrine Tumors (NET) Of Gastrointestinal (GI) Or Lung Origin

In a randomized, controlled trial (RADIANT-4) of AFINITOR (n = 202 treated) vs. placebo (n = 98 treated) in patients with advanced non-functional NET of GI or lung origin, the median age of patients was 63 years (22-86 years), 76% were White, and 53% were female. The median duration of exposure to AFINITOR was 9.3 months; 64% of patients were treated for > 6 months and 39% were treated for > 12 months. AFINITOR was discontinued for adverse reactions in 29% of patients, dose reduction or delay was required in 70% of AFINITOR-treated patients.

Serious adverse reactions occurred in 42% of AFINITOR-treated patients and included 3 fatal events (cardiac failure, respiratory failure, and septic shock). Adverse reactions occurring at an incidence of ≥ 10% and at ≥ 5% absolute incidence over placebo (all Grades) or ≥ 2% higher incidence over placebo (Grade 3 and 4) are presented in Table 10. Laboratory abnormalities are presented in Table 11.

Table 10: Adverse Reactions in ≥ 10% of AFINITOR-Treated Patients with Non-Functional NET of GI or Lung Origin in RADIANT-4

  AFINITOR
N = 202
Placebo
N = 98
All Grades
%
Grade 3-4
%
All Grades
%
Grade 3-4
%
Gastrointestinal
  Stomatitisa 63 9d 22 0
  Diarrhea 41 9 31 2d
  Nausea 26 3 17 1d
  Vomiting 15 4d 12 2d
General
  Peripheral edema 39 3d 6 1d
  Fatigue 37 5 36 1d
  Asthenia 23 3 8 0
  Pyrexia 23 2 8 0
Infections
  Infectionsb 58 11 29 2
Investigations
  Weight loss 22 2d 11 1d
Metabolism and nutrition
  Decreased appetite 22 2d 17 1d
Nervous system
  Dysgeusia 18 1d 4 0
Respiratory, thoracic and mediastinal
  Cough 27 0 20 0
  Dyspnea 20 3d 11 2
  Pneumonitisc 16 2d 2 0
  Epistaxis 13 1d 3 0
Skin and subcutaneous
  Rash 30 1d 9 0
  Pruritus 17 1d 9 0
Grading according to NCI CTCAE Version 4.03
a Includes stomatitis, mouth ulceration, aphthous stomatitis, gingival pain, glossitis, tongue ulceration, and mucosal inflammation.
b Urinary tract infection, nasopharyngitis, upper respiratory tract infection, lower respiratory tract infection (pneumonia, bronchitis), abscess, pyelonephritis, septic shock and viral myocarditis.
c Includes pneumonitis and interstitial lung disease.
d No Grade 4 adverse reactions were reported

Table 11: Selected Laboratory Abnormalities in ≥ 10% of AFINITOR-Treated Patients with Non-Functional NET of GI or Lung Origin in RADIANT-4

  AFINITOR
N = 202
Placebo
N = 98
All Grades
%
Grade 3-4
%
All Grades
%
Grade 3-4
%
Hematology
  Anemia 81 5a 41 2a
  Lymphopenia 66 16 32 2a
  Leukopenia 49 2a 17 0
  Thrombocytopenia 33 2 11 0
  Neutropenia 32 2a 15 3a
Chemistry
  Hypercholesterolemia 71 0 37 0
  Increased AST 57 2 34 2a
  Hyperglycemia (fasting) 55 6a 36 1a
  Increased ALT 46 5 39 1a
  Hypophosphatemia 43 4a 15 2a
  Hypertriglyceridemia 30 3 8 1a
  Hypokalemia 27 6 12 3a
  Hypoalbuminemia 18 0 8 0
Grading according to NCI CTCAE Version 4.03
a No Grade 4 laboratory abnormalities were reported.

Renal Cell Carcinoma (RCC)

The data described below reflect exposure to AFINITOR (n = 274) and placebo (n = 137) in a randomized, controlled trial (RECORD-1) in patients with metastatic RCC who received prior treatment with sunitinib and/or sorafenib. The median age of patients was 61 years (27 to 85 years), 88% were White, and 78% were male. The median duration of blinded study treatment was 141 days (19 to 451 days) for patients receiving AFINITOR.

The most common adverse reactions (incidence ≥ 30%) were stomatitis, infections, asthenia, fatigue, cough, and diarrhea. The most common Grade 3-4 adverse reactions (incidence ≥ 3%) were infections, dyspnea, fatigue, stomatitis, dehydration, pneumonitis, abdominal pain, and asthenia. The most common laboratory abnormalities (incidence ≥ 50%) were anemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, lymphopenia, and increased creatinine. The most common Grade 3-4 laboratory abnormalities (incidence ≥ 3%) were lymphopenia, hyperglycemia, anemia, hypophosphatemia, and hypercholesterolemia.

Deaths due to acute respiratory failure (0.7%), infection (0.7%), and acute renal failure (0.4%) were observed on the AFINITOR arm. The rate of adverse reactions resulting in permanent discontinuation was 14% for the AFINITOR group. The most common adverse reactions leading to treatment discontinuation were pneumonitis and dyspnea. Infections, stomatitis, and pneumonitis were the most common reasons for treatment delay or dose reduction. The most common medical interventions required during AFINITOR treatment were for infections, anemia, and stomatitis.

Adverse reactions reported with an incidence of ≥ 10% for patients receiving AFINITOR versus placebo are presented in Table 12. Laboratory abnormalities are presented in Table 13.

Table 12: Adverse Reactions Reported in ≥ 10% of Patients with RCC and at a Higher Rate in the AFINITOR Arm than in the Placebo Arm in RECORD-1

  AFINITOR
N = 274
Placebo
N = 137
All Grades
%
Grade 3-4
%
All Grades
%
Grade 3-4
%
Gastrointestinal
  Stomatitisa 44 4 8 0
  Diarrhea 30 2d 7 0
  Nausea 26 2d 19 0
  Vomiting 20 2d 12 0
Infections b 37 10 18 2
General
  Asthenia 33 4 23 4
  Fatigue 31 6d 27 4
  Edema peripheral 25 < 1d 8 < 1d
  Pyrexia 20 < 1d 9 0
  Mucosal inflammation 19 2d 1 0
Respiratory, thoracic and mediastinal
  Cough 30 < 1d 16 0
  Dyspnea 24 8 15 3d
  Epistaxis 18 0 0 0
  Pneumonitisc 14 4d 0 0
Skin and subcutaneous tissue
  Rash 29 1d 7 0
  Pruritus 14 < 1d 7 0
  Dry skin 13 < 1d 5 0
Metabolism and nutrition
  Anorexia 25 2d 14 < 1d
Nervous system
  Headache 19 1 9 < 1d
  Dysgeusia 10 0 2 0
Musculoskeletal and connective tissue
  Pain in extremity 10 1d 7 0
Grading according to NCI CTCAE Version 3.0
a Stomatitis (including aphthous stomatitis), and mouth and tongue ulceration.
b Includes all reported infections including, but not limited to, respiratory tract (upper and lower) infections, urinary tract infections, and skin infections.
c Includes pneumonitis, interstitial lung disease, lung infiltration, pulmonary alveolar hemorrhage, pulmonary toxicity, and alveolitis.
d No Grade 4 adverse reactions were reported.

Other notable adverse reactions occurring more frequently with AFINITOR than with placebo, but with an incidence of < 10% include:

Gastrointestinal: Abdominal pain (9%), dry mouth (8%), hemorrhoids (5%), dysphagia (4%)

General: Weight loss (9%), chest pain (5%), chills (4%), impaired wound healing (< 1%)

Respiratory, thoracic and mediastinal: Pleural effusion (7%), pharyngolaryngeal pain (4%), rhinorrhea (3%)

Skin and subcutaneous tissue: Hand-foot syndrome (reported as palmar-plantar erythrodysesthesia syndrome) (5%), nail disorder (5%), erythema (4%), onychoclasis (4%), skin lesion (4%), acneiform dermatitis (3%), angioedema (< 1%)

Metabolism and nutrition: Exacerbation of pre-existing diabetes mellitus (2%), new onset of diabetes mellitus (< 1%)

Psychiatric: Insomnia (9%)

Nervous system: Dizziness (7%), paresthesia (5%)

Ocular: Eyelid edema (4%), conjunctivitis (2%)

Vascular: Hypertension (4%), deep vein thrombosis (< 1%)

Renal and urinary: Renal failure (3%)

Cardiac: Tachycardia (3%), congestive cardiac failure (1%)

Musculoskeletal and connective tissue: Jaw pain (3%)

Hematologic: Hemorrhage (3%)

Table 13: Selected Laboratory Abnormalities Reported in Patients with RCC at a Higher Rate in the AFINITOR Arm than the Placebo Arm in RECORD-1

  AFINITOR
N = 274
Placebo
N =137
All Grades
%
Grade 3-4
%
All Grades
%
Grade 3-4
%
Hematologya
  Anemia 92 13 79 6
  Lymphopenia 51 18 28 5b
  Thrombocytopenia 23 1b 2 < 1
  Neutropenia 14 < 1 4 0
Chemistry
  Hypercholestermia 77 4b 35 0
  Hypertriglyceridemia 73 < 1b 34 0
  Hyperglycemia 57 16 25 2b
  Increased creatinine increased 50 2b 34 0
  Hypophosphatemia 37 6b 8 0
  Increased AST 25 1 7 0
  Increased ALT 21 1b 4 0
  Hyperbilirubinemia 3 1 2 0
Grading according to NCI CTCAE Version 3.0
a Reflects corresponding adverse drug reaction reports of anemia, leukopenia, lymphopenia, neutropenia, and thrombocytopenia (collectively pancytopenia), which occurred at lower frequency.
b No Grade 4 laboratory abnormalities were reported.

Tuberous Sclerosis Complex (TSC)-Associated Renal Angiomyolipoma

The data described below are based on a randomized (2:1), double-blind, placebo-controlled trial (EXIST-2) of AFINITOR in 118 patients with renal angiomyolipoma as a feature of TSC (n = 113) or sporadic lymphangioleiomyomatosis (n = 5). The median age of patients was 31 years (18 to 61 years), 89% were White, and 34% were male. The median duration of blinded study treatment was 48 weeks (2 to 115 weeks) for patients receiving AFINITOR.

The most common adverse reaction reported for AFINITOR (incidence ≥ 30%) was stomatitis. The most common Grade 3-4 adverse reactions (incidence ≥ 2%) were stomatitis and amenorrhea. The most common laboratory abnormalities (incidence ≥ 50%) were hypercholesterolemia, hypertriglyceridemia, and anemia. The most common Grade 3-4 laboratory abnormality (incidence ≥ 3%) was hypophosphatemia.

The rate of adverse reactions resulting in permanent discontinuation was 3.8% in the AFINITOR-treated patients. Adverse reactions leading to permanent discontinuation in the AFINITOR arm were hypersensitivity/angioedema/bronchospasm, convulsion, and hypophosphatemia. Dose adjustments (interruptions or reductions) due to adverse reactions occurred in 52% of AFINITOR-treated patients. The most common adverse reaction leading to AFINITOR dose adjustment was stomatitis.

Adverse reactions reported with an incidence of ≥ 10% for patients receiving AFINITOR and occurring more frequently with AFINITOR than with placebo are presented in Table 14. Laboratory abnormalities are presented in Table 15.

Table 14: Adverse Reactions Reported in ≥ 10% of AFINITOR-Treated Patients with TSC-Associated Renal Angiomyolipoma in EXIST-2

  AFINITOR
N = 79
Placebo
N = 39
All Grades
%
Grade 3-4
%
All Grades
%
Grade 3-4
%
Gastrointestinal
  Stomatitisa 78 6b 23 0
  Vomiting 15 0 5 0
  Diarrhea 14 0 5 0
General
  Peripheral edema 13 0 8 0
Infections
  Upper respiratory tract infection 11 0 5 0
Musculoskeletal and connective tissue
  Arthralgia 13 0 5 0
Respiratory, thoracic and mediastinal
  Cough 20 0 13 0
Skin and subcutaneous tissue
  Acne 22 0 5 0
Grading according to NCI CTCAE Version 3.0
a Includes stomatitis, aphthous stomatitis, mouth ulceration, gingival pain, glossitis, and glossodynia.
b No Grade 4 adverse reactions were reported.

Amenorrhea occurred in 15% of AFINITOR-treated females (8 of 52). Other adverse reactions involving the female reproductive system were menorrhagia (10%), menstrual irregularities (10%), and vaginal hemorrhage (8%).

The following additional adverse reactions occurred in less than 10% of AFINITOR-treated patients: epistaxis (9%), decreased appetite (6%), otitis media (6%), depression (5%), abnormal taste (5%), increased blood luteinizing hormone (LH) levels (4%), increased blood follicle stimulating hormone (FSH) levels (3%), hypersensitivity (3%), ovarian cyst (3%), pneumonitis (1%), and angioedema (1%).

Table 15: Selected Laboratory Abnormalities Reported in AFINITOR-Treated Patients with TSC-Associated Renal Angiomyolipoma in EXIST-2

  AFINITOR
N = 79
Placebo
N =39
All Grades
%
Grade 3-4
%
All Grades
%
Grade 3-4
%
Hematology
  Anemia 61 0 21 0
  Leukopenia 37 0 21 0
  Neutropenia 25 1 26 0
  Lymphopenia 20 1a 8 0
  Thrombocytopenia 19 0 3 0
Chemistry
  Hypercholestermia 85 1a 46 0
  Hypertriglyceridemia 52 0 10 0
  Hypophosphatemia 49 5a 15 0
  Increased alkaline phosphatase 32 1a 10 0
  Increased AST 23 1a 8 0
  Increased ALT 20 1a 15 0
  Hyperglycemia (fasting) 14 0 8 0
  Hyperbilirubinemia 3 1 2 0
Grading according to NCI CTCAE Version 3.0
a No Grade 4 laboratory abnormalities were reported.

Updated safety information from 112 patients treated with AFINITOR for a median duration of 3.9 years identified the following additional adverse reactions and selected laboratory abnormalities: increased partial thromboplastin time (63%), increased prothrombin time (40%), decreased fibrinogen (38%), urinary tract infection (31%), proteinuria (18%), abdominal pain (16%), pruritus (12%), gastroenteritis (12%), myalgia (11%), and pneumonia (10%).

TSC-Associated Subependymal Giant Cell Astrocytoma (SEGA)

The data described below are based on a randomized (2:1), double-blind, placebo-controlled trial (EXIST-1) of AFINITOR in 117 patients with SEGA and TSC. The median age of patients was 9.5 years (0.8 to 26 years), 93% were White, and 57% were male. The median duration of blinded study treatment was 52 weeks (24 to 89 weeks) for patients receiving AFINITOR.

The most common adverse reactions reported for AFINITOR (incidence ≥ 30%) were stomatitis and respiratory tract infection. The most common Grade 3-4 adverse reactions (incidence ≥ 2%) were stomatitis, pyrexia, pneumonia, gastroenteritis, aggression, agitation, and amenorrhea. The most common key laboratory abnormalities (incidence ≥ 50%) were hypercholesterolemia and elevated partial thromboplastin time. The most common Grade 3-4 laboratory abnormality (incidence ≥ 3%) was neutropenia.

There were no adverse reactions resulting in permanent discontinuation. Dose adjustments (interruptions or reductions) due to adverse reactions occurred in 55% of AFINITOR-treated patients. The most common adverse reaction leading to AFINITOR dose adjustment was stomatitis.

Adverse reactions reported with an incidence of ≥ 10% for patients receiving AFINITOR and occurring more frequently with AFINITOR than with placebo are reported in Table 16. Laboratory abnormalities are presented in Table 17.

Table 16: Adverse Reactions Reported in ≥ 10% of AFINITOR-Treated Patients with TSC-Associated SEGA in EXIST-1

  AFINITOR
N = 78
Placebo
N = 39
All Grades
%
Grade 3-4
%
All Grades
%
Grade 3-4
%
Gastrointestinal        
  Stomatitisa 62 9f 26 3f
  Vomiting 22 1f 13 0
  Diarrhea 17 0 5 0
  Constipation 10 0 3 0
Infections        
  Respiratory tract infectionb 31 3 23 0
  Gastroenteritisc 10 5 3 0
  Pharyngitis streptococcal 10 0 3 0
General        
  Pyrexia 23 6f 18 3f
  Fatigue 14 0 3 0
Psychiatric        
  Anxiety, aggression or other behavioral disturbanced 21 5f 3 0
Skin and subcutaneous tissue        
  Rashe 21 0 8 0
  Acne 10 0 5 0
Grading according to NCI CTCAE Version 3.0
a Includes mouth ulceration, stomatitis, and lip ulceration
b Includes respiratory tract infection, upper respiratory tract infection, and respiratory tract infection viral
c Includes gastroenteritis, gastroenteritis viral, and gastrointestinal infection
d Includes agitation, anxiety, panic attack, aggression, abnormal behavior, and obsessive compulsive disorder
eIncludes rash, rash generalized, rash macular, rash maculo-papular, rash papular, dermatitis allergic, and urticaria
f No Grade 4 adverse reactions were reported.

Amenorrhea occurred in 17% of AFINITOR-treated females aged 10 to 55 years (3 of 18). For this same group of AFINITOR-treated females, the following menstrual abnormalities were reported: dysmenorrhea (6%), menorrhagia (6%), metrorrhagia (6%), and unspecified menstrual irregularity (6%).

The following additional adverse reactions occurred in less than 10% of AFINITOR-treated patients: nausea (8%), pain in extremity (8%), insomnia (6%), pneumonia (6%), epistaxis (5%), hypersensitivity (3%), increased blood luteinizing hormone (LH) levels (1%), and pneumonitis (1%).

Table 17: Selected Laboratory Abnormalities Reported in AFINITOR-Treated Patients with TSC-Associated SEGA in EXIST-1

  AFINITOR
N = 78
Placebo
N = 39
All Grades
%
Grade 3-4
%
All Grades
%
Grade 3-4
%
Hematology        
  Elevated partial thromboplastin time 72 3a 44 5a
  Neutropenia 46 9a 41 3a
  Anemia 41 0 21 0
Chemistry        
  Hypercholesterolemia 81 0 39 0
  Elevated aspartate transaminase (AST) 33 0 0 0
  Hypertriglyceridemia 27 0 15 0
  Elevated alanine transaminase (ALT) 18 0 3 0
  Hypophosphatemia 9 1a 3 0
Grading according to NCI CTCAE Version 3.0
a No Grade 4 laboratory abnormalities were reported.

Updated safety information from 111 patients treated with AFINITOR for a median duration of 47 months identified the following additional notable adverse reactions and key laboratory abnormalities: decreased appetite (14%), hyperglycemia (13%), hypertension (11%), urinary tract infection (9%), decreased fibrinogen (8%), cellulitis (6%), abdominal pain (5%), decreased weight (5%), elevated creatinine (5%), and azoospermia (1%).

TSC-Associated Partial-Onset Seizures

The data described below are based on the 18-week Core phase of a randomized, double-blind, multicenter, three-arm trial (EXIST-3) comparing two everolimus trough levels (3-7 ng/mL and 9-15 ng/mL) to placebo as adjunctive antiepileptic therapy in patients with TSC-associated partial-onset seizures. A total of 366 patients were randomized to AFINITOR DISPERZ low trough (LT) (n = 117), AFINITOR DISPERZ high trough (HT) (n = 130), or placebo (n = 119). The median age of patients was 10 years (2.2 to 56 years; 28% were < 6 years, 31% were 6 to < 12 years, 22% were 12 to < 18 years, and 18% were ≥ 18 years), 65% were White, and 52% were male. Patients received between one and three concomitant antiepileptic drugs.

The most common adverse reaction reported for AFINITOR DISPERZ in both arms (incidence ≥ 30%) was stomatitis. The most common Grade 3-4 adverse reactions (incidence ≥ 2%) were stomatitis, pneumonia, and irregular menstruation. The most common laboratory abnormality (incidence ≥ 50%) was hypercholesterolemia. The most common Grade 3-4 laboratory abnormality (incidence ≥ 2%) was neutropenia.

Adverse reactions leading to study drug discontinuation occurred in 5% and 3% of patients in the LT and HT arms, respectively. The most common adverse reaction (incidence ≥ 1%) leading to discontinuation was stomatitis. Dose adjustments (interruptions or reductions) due to adverse reactions occurred in 24% and 35% of patients in the LT and HT arms, respectively. The most common adverse reactions (incidence ≥ 3%) leading to dose adjustments in the AFINITOR DISPERZ arms were stomatitis, pneumonia, and pyrexia.

Adverse reactions reported with an incidence of ≥ 10% for patients receiving AFINITOR DISPERZ are presented in Table 18. Laboratory abnormalities are presented in Table 19.

Table 18: Adverse Reactions Reported in ≥ 10% of AFINITOR DISPERZ-Treated Patients with TSC-Associated Partial-Onset Seizures in EXIST-3

  AFINITOR DISPERZ Placebo
Target of 3-7 ng/mL Target of 9-15 ng/mL    
N = 117 N = 130 N = 119
All Grades
%
Grade 3-4
%
All Grades
%
Grade 3-4
%
All Grades
%
Grade 3-4
%
Gastrointestinal            
  Stomatitisa 55 3b 64 4b 9 0
  Diarrhea 17 0 22 0 5 0
  Vomiting 12 0 10 2b 9 0
Infections            
  Nasopharyngitis 14 0 16 0 16 0
  Upper respiratory tract infection 13 0 15 0 13 0.8b
General            
  Pyrexia 20 0 14 0.8b 5 0
Respiratory, thoracic and mediastinal            
  Cough 11 0 10 0 3 0
Skin and subcutaneous tissue            
  Rash 6 0 10 0 3 0
a Includes stomatitis, mouth ulceration, aphthous ulcer, lip ulceration, tongue ulceration, mucosal inflammation, gingival pain
b No Grade 4 adverse reactions were reported.

The following additional adverse reactions occurred in < 10% of AFINITOR DISPERZ treated patients (% AFINITOR LT, % AFINITOR HT): decreased appetite (9%, 7%), pneumonia (2%, 4%), aggression (2%, 0.8%), proteinuria (0%, 2%), menorrhagia (0.9%, 0.8%), and pneumonitis (0%, 0.8%).

Table 19: Selected Laboratory Abnormalities Reported in ≥ 10% AFINITOR DISPERZ-Treated Patients with TSC-Associated Partial-Onset Seizures

  AFINITOR DISPERZ Placebo
Target of 3-7 ng/mL Target of 9-15 ng/mL    
N = 117 N = 130 N = 119
All Grades
%
Grade 3-4
%
All Grades
%
Grade 3-4
%
All Grades
%
Grade 3-4
%
Hematology            
  Neutropenia 25 4a 37 6 23 7a
  Anemia 27 0.9a 30 0 21 0.8a
  Thrombocytopenia 12 0 15 0 6 0
Chemistry            
  Hypercholesterolemia 86 0 85 0.8a 58 0
  Hypertriglyceridemia 43 2a 39 2 22 0
  Increased ALT 17 0 22 0 6 0
  Increased AST 13 0 19 0 4 0
  Hyperglycemia 19 0 18 0 17 0
  Increased alkaline phosphatase 24 0 16 0 29 0
  Hypophosphatemia 9 0.9a 16 2 3 0
Grading according to NCI CTCAE version 4.03
a No Grade 4 laboratory abnormalities were reported.

Updated safety information from 357 patients treated with AFINITOR DISPERZ for a median duration of 48 weeks identified the following additional notable adverse reactions: hypersensitivity (0.6%), angioedema (0.3%), and ovarian cyst (0.3%).

Postmarketing Experience

The following adverse reactions have been identified during post approval use of AFINITOR/AFINITOR DISPERZ. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate frequency or establish a causal relationship to drug exposure:

  • Gastrointestinal: Acute pancreatitis
  • Hepatobiliary: Cholecystitis and cholelithiasis
  • Vascular: Arterial thrombotic events
  • Nervous System: Reflex sympathetic dystrophy
  • Cardiac: Cardiac failure with some cases reported with pulmonary hypertension (including pulmonary arterial hypertension) as a secondary event
  • Infections: Sepsis and septic shock

Read the entire FDA prescribing information for Afinitor (Everolimus Tablets)

Related Resources for Afinitor

Related Health

Read the Afinitor User Reviews »

© Afinitor Patient Information is supplied by Cerner Multum, Inc. and Afinitor Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

SLIDESHOW

Skin Cancer Symptoms, Types, Images See Slideshow

Health Solutions From Our Sponsors

CONTINUE SCROLLING FOR RELATED SLIDESHOW